Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$86.50Cboe Real-Time Last Sale as of 3:59PM ET 5/23/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.32(0.37%)
Bid (Size)$86.17 (100)
Ask (Size)$86.76 (100)
Day Low / High$85.54 - 87.61
Volume294.8 K

View Biotechnology IndustryPeer Comparison as of 05/23/2022


Neurocrine Biosciences Inc ( NASDAQ )

Price: $86.50
Change: +0.32 (0.37%)
Volume: 294.8 K
3:59PM ET 5/23/2022

Exact Sciences Corp ( NASDAQ )

Price: $51.91
Change: -1.26 (2.37%)
Volume: 1.1 M
3:58PM ET 5/23/2022

Halozyme Therapeutics Inc ( NASDAQ )

Price: $44.30
Change: -0.02 (0.05%)
Volume: 460.1 K
3:59PM ET 5/23/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Exelixis Inc ( NASDAQ )

Price: $17.75
Change: -0.02 (0.08%)
Volume: 2.0 M
3:59PM ET 5/23/2022

Read more news Recent News

Neurocrine Biosciences Gets FDA's Orphan Drug Designation for Experimental Huntington Disease Drug
3:42AM ET 5/13/2022 MT Newswires

Neurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...

Insider Sell: Neurocrine Biosciences
5:41PM ET 5/11/2022 MT Newswires

Richard F Pops, Director, on May 09, 2022, sold 15,000 shares in Neurocrine Biosciences (NBIX) for $1,144,463. Following the Form 4 filing with the SEC,...

Earnings Reaction History: Neurocrine Biosciences, 33.3% Follow-Through Indicator, 4.8% Sensitive
12:39PM ET 5/04/2022 MT Newswires

Expected Earnings Release: 05/04/2022, After-hours Avg. Extended-Hours Dollar Volume: $11,976,203 Neurocrine Biosciences (NBIX) is due to issue its...

--Wedbush Adjusts Price Target for Neurocrine Biosciences to $103 From $104, Maintains Outperform Rating
11:45AM ET 5/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Number of Employees585
Recent SEC Filing05/20/20224
Chief Executive Officer & DirectorKevin Charles Gorman
Vice President-Information Technology & OperationsBill Wilson
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis

Company Highlights

Price Open$86.36
Previous Close$86.18
52 Week Range$71.88 - 108.02
Market Capitalization$8.3 B
Shares Outstanding95.6 M
SectorHealth Technology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings119.69
Earnings per Share$1.21
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin5.91%
Return on Equity5.30%

Analyst Ratings as of 04/21/2022

Consensus RecommendationConsensus Icon
Powered by Factset